Table 3.
Characteristics of the Hybrid and Vac groups at the time of serology.
| Hybrid group | Vac group | |
|---|---|---|
| N (%) | 15/39 (38.5%) | 24/39 (61.5%) |
| Male/female | 11/4 | 14/10 |
| Median age in years (IQR) | 53 (50–66) | 60 (38–67) |
| Median time from kidney transplantation in years (IQR) | 7 (2–11) | 9 (0.7–15) |
| Number of kidney transplantations n = 1 n = 2 |
13 2 |
20 4 |
| Median time from COVID-19 in daysa (IQR) | 237 (88–373) | - |
| Transplanted before COVID-19b | 13 or 14/15 (86% or 93%) | - |
| Vaccinated before COVID-19b (%) | 7/13 (54%) | - |
| Median vaccine dose number before COVID-19a (IQR) | 2 (0–2) | - |
| Median vaccine dose number before serology (IQR) | 3 (2–4) | 3 (3–4) |
| Median time from the last known immunizing event before serology in daysc (IQR) | 84 (60–95) | 99 (67–134) |
| Median estimated GFR in mL/min/1.73 m2 (IQR) | 38 (31–60) | 48 (31–57) |
| Median concentration of anti-spike Ab in BAU/mL (IQR) | 1,830 (1,231–8,425) | 1,385 (984–1,997) |
| N neutralizing ≥ one variant (%) | 14/15 (93%) | 18/24 (75%) |
a
Two kidney transplant recipients (KTRs) without prior PCR-proven COVID-19 were shown to have positive Western blot serology against the nucleocapsid protein, with no possibility to date the infection. Median time from COVID-19 was calculated for the 13 others.
b
One of these 2 KTRs diagnosed with prior COVID-19 using Western blot has been transplanted before the pandemic. For the second one, it is impossible to know the temporality between COVID-19 and kidney transplantation. Thus, the numerator is 13 or 14.
c
Immunizing events were vaccination or COVID-19. Interquartile (IQR).